Incidence and correlates of tardive dyskinesia in first episode of schizophrenia

被引:0
|
作者
Chakos, MH [1 ]
Alvir, JMJ [1 ]
Woerner, MG [1 ]
Koreen, A [1 ]
Geisler, S [1 ]
Mayerhoff, D [1 ]
Sobel, S [1 ]
Kane, JM [1 ]
Borenstein, M [1 ]
Lieberman, JA [1 ]
机构
[1] ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,HILLSIDE HOSP,DEPT PSYCHIAT,GLEN OAKS,NY
关键词
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: There is controversy over whether tardive dyskinesia (TD) is solely a consequence of antipsychotic drug treatment or in part may reflect an intrinsic aspect of the disease process. Pathophysiologic factors could, independently or in concert with drug effects, lead to the development of dyskinetic signs. Methods: We studied prospectively 118 patients in their first episode of psychosis who were treatment-naive or had less than 12 weeks of antipsychotic drug exposure at study entry. Patients received standardized antipsychotic drug treatment and were evaluated for up to 81/2 years with regular assessments of psychopathologic signs and symptoms and side effects. Results: The cumulative incidence of presumptive TD was 6.3% after 1 year of follow-up, 11.5% after 2 years, 13.7% after 3 years, and 17.5% after 4 years. Persistent TD had a cumulative incidence of 4.8% after 1 year, 7.2% after 2 years, and 15.6% after 4 years. Taken individually, both antipsychotic drug dose, entered as a time-dependent covariate, and poor response to treatment of the first psychotic episode were significant predicters of time to TD. When antipsychotic drug dose and treatment response were examined together, treatment responders had significantly lower hazards for presumptive TD than nonresponders (hazard ratio, 0.29; 95% confidence interval, 0.09 to 0.97). Dose was a trend-level predicter, with each 100-mg chlorpromazine equivalent unit increase in dose associated with a 5% increase in the hazard of presumptive TD (hazard ratio, 1.05; 95% confidence interval, 0.99 to 1.11). Conclusion: Poor response to the treatment of a first episode of psychosis and, to a lesser extent, antipsychotic drug dose are important factors in the development of TD. This suggests that there may be a disease-related vulnerability to TD manifest with antipsychotic drug exposure. Potential pathophysiologic factors might include neurodevelopmentally induced structural neuropathologic characteristics, sensitization of nigrostriatal dopamine neurons, and the induction of glutamatergically mediated neurotoxic effects.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 50 条
  • [31] Neuropsychology of First Episode Schizophrenia: Characterization and Clinical Correlates
    Doshi, Vimal V.
    INDIAN JOURNAL OF PSYCHIATRY, 2015, 57 (05) : S8 - S8
  • [32] Neuropsychological correlates of prodromal symptoms in first episode schizophrenia
    Wölwer, W
    Gaebel, W
    EUROPEAN PSYCHIATRY, 2005, 20 : S48 - S48
  • [33] Neuropsychological correlates of symptom profiles in first episode schizophrenia
    Lucas, S
    Fitzgerald, D
    Redoblado-Hodge, MA
    Anderson, J
    Sanbrook, M
    Harris, A
    Brennan, J
    SCHIZOPHRENIA RESEARCH, 2004, 71 (2-3) : 323 - 330
  • [34] Clinical correlates of insight in first-episode schizophrenia
    Mutsatsa, SH
    Hutton, SB
    Gibbins, H
    Dibnah, C
    Joyce, EM
    Barnes, TR
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 18 - 18
  • [35] Electrophysiological correlates of planning and monitoring in first episode schizophrenia
    Woelwer, Wolfgang
    Stroth, Sanna
    Brinkmeyer, Jurgen
    Gaebel, Wolfgang
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2012, 203 (01) : 83 - 88
  • [36] First-episode schizophrenia: characterization and clinical correlates
    Bilder, Robert M.
    Goldman, Robert S.
    Robinson, Delbert
    Reiter, Gail
    Bell, Lisa
    Bates, John A.
    Pappadopulos, Elizabeth
    Alvir, Jose Maria J.
    Woerner, Margaret G.
    Geisler, Stephen
    Kane, John M.
    NEUROPSYCHOLOGICAL TRENDS, 2007, (02) : 7 - 30
  • [37] Incidence of tardive dyskinesia in patients receiving first or second generation antipsychotic therapy
    Tapp, A.
    Wood, A.
    Kilzieh, N.
    Martin, L.
    Kennedy, A.
    Raskind, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S420 - S420
  • [38] Schizophrenia: Is Tardive Dyskinesia rarer in newer Antipsychotics?
    Klein, Jan Philipp
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2019, 87 (08) : 404 - +
  • [39] TARDIVE-DYSKINESIA AND POSITIVE SYMPTOMS OF SCHIZOPHRENIA
    WHITE, T
    BROWN, KW
    WOODS, JP
    ACTA PSYCHIATRICA SCANDINAVICA, 1991, 83 (05) : 377 - 379
  • [40] Olanzapine improves tardive dyskinesia in patients with schizophrenia
    Kinon, BJ
    Stauffer, VL
    Wang, L
    Thi, KT
    ANNALS OF NEUROLOGY, 2002, 52 (03) : S88 - S88